Squamous Cell Carcinoma of Head and Neck Clinical Trials

18 studies are recruiting for squamous cell carcinoma of head and neck in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

   This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the p…

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   Highlands Oncology Group, PA, Fayetteville, Arkansas

   Locations

   6 in total

   Run by

   University of Arkansas

   See if you can join NCT05952934 on ClinicalTrials.gov

2. A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

   The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metastatic head and neck …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Colorado Denver Anschultz Medical Campus, Aurora, Colorado

   Locations

   56 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06385080 on ClinicalTrials.gov

3. A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

   This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a t…

   Stage

   Phase 1

   Ages

   18 to 74

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   19 in total

   Run by

   Johnson & Johnson Enterprise Innovation Inc.

   See if you can join NCT07219212 on ClinicalTrials.gov

4. A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

   The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ironwood Cancer and Research Center, Chandler, Arizona

   Locations

   201 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07276399 on ClinicalTrials.gov

5. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

   The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Community Cancer Institute, Clovis, California

   Locations

   47 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT04895709 on ClinicalTrials.gov

6. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

7. A Study of DM005 in Patients With Advanced Solid Tumors

   The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors. DM005 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. For each participant, there will be…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Cancer Institute, Detroit, Michigan

   Locations

   6 in total

   Run by

   Doma Biopharmaceutical（Suzhou）Co., Ltd.

   See if you can join NCT06515990 on ClinicalTrials.gov

8. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

   This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Alaska Oncology and Hematology, Anchorage, Alaska

   Locations

   158 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT04389632 on ClinicalTrials.gov

9. 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

   This study is being done because both 5-azacytidine and nivolumab can influence the immune system's response to HPV-associated head and neck cancer, and we wish to evaluate whether taking 5-azacytidine will make HPV-associated head and neck cancer more sensitive to treatment with nivolumab. 5-Azacy…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Run by

   Barbara Burtness

   See if you can join NCT05317000 on ClinicalTrials.gov

10. 5-Fluorouracil Response and Optimization STudy (The FROST Trial)

    This randomized phase II trial will characterize the efficacy, adverse event (AE) profile, and safety of two regimens of 5-FU given as 2L+ treatment to patients with RM-HNSCC. Eligible patients for this trial will have previously received platinum and PD-1 inhibitor therapy. The experimental regime…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07419464 on ClinicalTrials.gov

11. Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

    The goal of this clinical trial is to learn if drug CADI-05, when used together with pembrolizumab (an FDA approved immunotherapy), can help treat locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in adults. It will also learn about the safety of drug CADI-05. The main questions it …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Fox Chase Cancer Center, Philadelphia, Pennsylvania

    Locations

    2 in total

    Run by

    Fox Chase Cancer Center

    See if you can join NCT07455032 on ClinicalTrials.gov

12. A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

    The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07063212 on ClinicalTrials.gov

13. Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

    This research study is studying the effect of different drugs as possible treatments for salivary and other head and neck cancers/ The name of the study intervention involved in this study is: -- implantable microdevice

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Brigham and Women's Hospital

    See if you can join NCT05553782 on ClinicalTrials.gov

14. Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma

    This is a single-center, non-interventional, observational study that evaluates the correlation of circulating tumor DNA (ctDNA) testing to cancer relapse for participants with squamous cell carcinomas (HNC) of the head and neck mucosa and skin after curative-intent primary radiation or surgery.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT06606028 on ClinicalTrials.gov

15. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moores Cancer Center UC San Diego Health, La Jolla, California

    Locations

    20 in total

    Run by

    Bicara Therapeutics

    See if you can join NCT04429542 on ClinicalTrials.gov

16. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sharp Memorial Hospital, San Diego, California

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

17. Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

    This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachusetts Eye and Ear, Boston, Massachusetts

    Run by

    Massachusetts Eye and Ear Infirmary

    See if you can join NCT06744296 on ClinicalTrials.gov

18. Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

    This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indicat…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Yale, New Haven, Connecticut

    Locations

    15 in total

    Run by

    IO Biotech

    See if you can join NCT05280314 on ClinicalTrials.gov